Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
- PMID: 27459306
- PMCID: PMC4973800
- DOI: 10.12659/msm.896843
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Abstract
BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks. MATERIAL AND METHODS Two hundred patients were divided into 2 groups: in Group I, patients were provided with a single pill containing amlodipine/atorvastatin (5/20 mg) to be taken each night at 10 pm, and in Group II, patients were taking amlodipine (5 mg) and atorvastatin (20 mg) each morning at 7 am. RESULTS Our results indicated no obvious difference in blood pressure control between the 2 groups. Taking amlodipine at night not only lowered blood pressure, but it also provided better control during the peak blood pressure in the morning. Hypercholesterolemia control in the 2 groups was also not significantly different, taking atorvastatin in the morning was as effective as dosing at night in patients with hypercholesterolemia. While the carotid IMT, hs-CRP, and LVMI were significantly lower after treatment, no differences were found between the 2 groups. Although no obvious difference was found in adverse drug reactions between the 2 groups, compliance was much better in the single-pill group than in patients taking the 2 medications separately. CONCLUSIONS In conclusion, single-pill amlodipine-atorvastatin taken at night can lower blood pressure and reduce the morning peak blood pressure levels the next day. Additionally, this dosing method could improve patient adherence to the therapy.
Figures




Similar articles
-
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.Mayo Clin Proc. 2008 Jan;83(1):35-45. doi: 10.4065/83.1.35. Mayo Clin Proc. 2008. PMID: 18174006 Clinical Trial.
-
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.Am J Cardiovasc Drugs. 2010;10(3):193-202. doi: 10.2165/11530680-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20387911
-
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].Orv Hetil. 2016 Mar 13;157(11):425-9. doi: 10.1556/650.2016.30401. Orv Hetil. 2016. PMID: 26947091 Hungarian.
-
A single-pill combination of amlodipine besylate and atorvastatin calcium (update).Drugs Today (Barc). 2007 Mar;43(3):157-77. doi: 10.1358/dot.2007.43.3.1079878. Drugs Today (Barc). 2007. PMID: 17380213 Review.
-
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.Int J Clin Pract. 2005 Jul;59(7):839-46. doi: 10.1111/j.1368-5031.2005.00601.x. Int J Clin Pract. 2005. PMID: 15963213 Review.
Cited by
-
Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.Diagn Pathol. 2023 Sep 28;18(1):108. doi: 10.1186/s13000-023-01393-x. Diagn Pathol. 2023. PMID: 37759223 Free PMC article. Clinical Trial.
-
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.Cochrane Database Syst Rev. 2017 Mar 6;3(3):CD009868. doi: 10.1002/14651858.CD009868.pub3. Cochrane Database Syst Rev. 2017. PMID: 28263370 Free PMC article.
-
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.Acta Clin Croat. 2018 Sep;57(3):464-472. doi: 10.20471/acc.2018.57.03.09. Acta Clin Croat. 2018. PMID: 31168179 Free PMC article.
References
-
- Liu LS Writing Group of Chinese Guidelines for the Management of H. [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579–615. [in Chinese] - PubMed
-
- Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281–86. - PubMed
-
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57. - PubMed
-
- Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387–92. - PubMed
-
- Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA. 2001;285:1711–18. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous